Dr Harold Burstein gets an oncologist's behind-the- cameras view of 'Cancer: The Emperor of All Maladies,' from Barak Goodman, director of the Ken Burns documentary.

Dr John Marshall asks tough questions of experts at the 2014 Ruesch Symposium about whether information gained from molecular testing can tailor therapy and lower costs.

Can immunotherapy 'clip the force field' of gastrointestinal tumors? Dr John Marshall and experts say yes and will discuss advances during the Ruesch Symposium 2014, December 5, Washington, DC.

Dr Tony Fauci gives straightforward answers to lingering questions about Ebola in the United States.

A tripling of response with nivolumab and the first study in which a BRAF/MEK combo increases overall survival are among the melanoma highlights at ESMO 2014, reported by Dr Antoni Ribas.

Does population screening for BRCA mutations portend a eugenics future, as in 'Gattaca,' or a practical means to reduce the risk for breast and ovarian cancer? Dr. Kathy Miller weighs the issues.

A new multitargeted stool-based screening test could be the answer for patients who avoid colonoscopy. Dr. David Johnson offers commentary, and a couple of caveats, on its use in clinical practice.

The ability of mutant protein to spread to healthy brain tissue is explored in this study of patients who died from Huntington disease.

Dr. Mark Kris discusses how to reliably detect ALK-positive lung adenocarcinomas and how to use new therapies -- in particular the drug ceritinib -- to treat these patients.

Ileana Piña explains the role of BNP in heart failure management today and what she hopes to learn from the GUIDE-IT study.